Macrophage-directed Therapies Summit 2021

The annual Macrophage-directed Therapies Summit returns as the leading industry focused summit dedicated to delivering clinical proof of concept through the effective translation of macrophage-directed therapies whilst ensuring safety, control and effective combination strategies.

Across 3 days of carefully curated sessions, we will gather with over 100 of the leading c-level executives and KOLs in macrophage clinical development from the likes of CARISMA therapeutics, Merck, Arch Oncology, Pionyr and Trillium to change the foundation of treatment by modulating the behavior and function of macrophage therapies.

In 2021, take advantage of 2 tracks of cutting-edge content from targeting "do not eat me" signals and beyond, to engineered macrophage therapies and interleukin directed approaches to ensure safety, reduce toxicity, manage, and control the plasticity of macrophages.

https://macrophage-directed-therapies.com/

28-30 September, 2021
9.00am-5:00pm EST | 6.00am-2:00pm PST

Contact:
info@hansonwade.com

Time: 9:00 am - 5:00 pm

Prices:

Drug Developers (Earlybird rates, focus day and workshops available): USD 2099.00,
Academic (Earlybird rates and workshops available): USD 1899.00,
Service Providers (Earlybird rates and workshops available): USD 2499.00

URLs:

Brochure: https://go.evvnt.com/784998-0?pid=176

Tickets: https://go.evvnt.com/784998-1?pid=176

Speakers: Laura Helming, Head Myeloid Cell Research, Translational Innovation Platform Oncology and Immuno-Oncology, Merck, Michael Klichinsky, Co-Founder and VP, Discovery, Carisma Therapeutics, Moa Fransson, CEO, Genagon Therapeutics, Nicholas Poirier, CSO, OSE Immunotherapeutics, Tatiana Novobrantseva, Co-founder and CSO, Verseau Therapeutics, Vladimir Litvak, Senior Principal Scientist/Lab Head, Sanofi